New immunotherapy drug combinations are significantly extending survival for patients with advanced kidney cancer, one of the fastest-growing cancers in the United States, according to oncologists and ...

Editorial: Treatments continue to improve. The challenge now facing ministers is hugely unequal outcomes ...

SALT LAKE CITY — The five-year survival rate for all cancers combined has reached a historic 70%, according to the latest American Cancer Society Cancer Statistics 2026 report, based on all people ...

Belzutifan-lenvatinib slows progression versus cabozantinib with much longer response dura ...

The combination of belzutifan plus lenvatinib significantly improved outcomes for patients with clear cell renal cell ...

Add Yahoo as a preferred source to see more of our stories on Google. Kidney cancer cases are projected to nearly double by 2050, but researchers say prevention and early detection can help curb the ...

KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients ...

Huge improvements in prevention, diagnosis and treatment have driven the fall, Cancer Research UK says ...

Cognitive dysfunction in kidney cancer survivors is linked to treatment burden, stress, and fatigue, affecting daily functioning and quality of life. Antiangiogenic therapies in kidney cancer are ...